Gafar, Fajri
Boudewijn, Ilse M.
Cox, Claire A.
Vonk, Judith M.
Schokker, Siebrig
Lexmond, Anne J.
Frijlink, Henderik W.
Hagedoorn, Paul
Postma, Dirkje S.
van den Berge, Maarten
Funding for this research was provided by:
Teva Pharmaceutical Industries (-)
Article History
Received: 17 September 2018
Accepted: 4 December 2018
First Online: 18 December 2018
Consent for publication
: Not applicable.
: The University of Groningen received fees for consultancy for IMB from GlaxoSmithKline. Based on a patent of the Genuair of which PH and HWF are co-inventors, the University of Groningen received royalty payments from Astra Zeneca. PH received fees paid to the University of Groningen for patent of the Novolizer, Twincer and Cyclops and his employer receives royalties from the sales of the Novolizer and Genuair. DSP has received research grants from GlaxoSmithKline, fees for consultancies from Chiesi and Astra Zeneca, and speaker’s fees from Chiesi, all of which paid to the University of Groningen. MvdB has received grants paid to the University of Groningen from GlaxoSmithKline, Chiesi and TEVA Pharma. FG, CAC, JMV, AJL and SS do not have any conflict of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.